Elanco to sell dog treatment to Dechra Pharmaceuticals for $135 million to push forward acquisition of Bayer's animal health business
MLex Summary: Elanco will sell to Dechra Pharmaceuticals a dog treatment named Osurnia for $135 million, the company announced in a release. Elanco said it made the sale in order to...To view the full article, register now.
Already a subscriber? Click here to view full article